secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001140361-24-004321
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports preliminary 2023 KIMMTRAK revenue of $235M, announces $300M convertible notes offering
--------------------------------------------------------------------------------

- Q4 2023 KIMMTRAK net sales ~$66M; full-year 2023 net sales ~$235M.
- Cash and equivalents at Dec 31, 2023 ~$443M.
- Proposed $300M convertible senior notes due 2030; initial purchasers option for additional $45M.
- Net proceeds to accelerate clinical pipeline, expand commercial, and repay Pharmakon loans.
- Pipeline: tebentafusp Phase 2/3 cutaneous melanoma topline data expected Q4 2024; IMC-F106C Phase 3 first-line melanoma trial first patient randomization Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/0001140361-24-004321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/ef20020073_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-004321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer